Protagonist Therapeutics, Inc.
HealthcareNASDAQ:PTGX · NASDAQ Global Market
-$0.01 today
Vol 0.44M · Avg 0.73M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-21.2%
avg -23.5%
ROIC
-25.2%
avg -39.9%
ROA
-19.4%
avg -32.0%
Analysis
ROA is currently the strongest return metric at -19.4% versus its period average of -32.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Dinesh V. Patel | Chief Executive Officer, President, Secretary & Director | $1.41M | — | 69 | $523,478.00 | 0.81% |
Arturo Molina FACP | Chief Medical Officer | $949,992.00 | — | 67 | $99,115.00 | 0.15% |
Asif Ali | Executive Vice President & Chief Financial Officer | $826,242.00 | — | 52 | $59,003.00 | 0.09% |
Carena Spivey | Executive VP & Chief Human Resources Officer | — | — | — | — | — |
Ashok Bhandari | EVP & Chief Discovery Officer | — | — | 62 | — | — |
Newman Yeilding | Executive Vice President, Chief Scientific Officer | — | — | — | — | — |
Samuel R. Saks | Clinical Development Advisor | — | — | 71 | $90,000.00 | 0.14% |
Carter J. King | Executive Vice President of Business Development | — | — | 55 | — | — |
Matthew Gosling | Executive Vice President and Chief Legal & Business Officer | — | — | 55 | — | — |
Venkat Thalladi | EVP & Chief Technical Officer | — | — | — | — | — |
Abha Bommireddi | Executive Vice President & Chief of Staff | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
35
$50.13M
Net Sentiment
$50.13M
Net selling
Most Active
PATEL DINESH V PH D
11 transactions
1–10 of 35
Analysis
Insiders reported 0 buys worth $0.00 and 35 sells worth $50.13M over the last 12 months. That adds up to net selling of $50.13M. PATEL DINESH V PH D was the most active insider with 11 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +29.6% (12yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Forward estimates point to Revenue at +29.6% (12yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
TG Therapeutics, Inc.
NASDAQ:TGTX
$7.58B
Alkermes plc
NASDAQ:ALKS
$7.38B
Kymera Therapeutics, Inc.
NASDAQ:KYMR
$7.09B
Immunovant, Inc.
NASDAQ:IMVT
$6.90B
Arcellx, Inc.
ACLX
$6.73B
PTC Therapeutics, Inc.
NASDAQ:PTCT
$6.23B
Akero Therapeutics, Inc.
AKRO
$4.50B
Crinetics Pharmaceuticals, Inc.
NASDAQ:CRNX
$3.63B
NewAmsterdam Pharma Company N.V.
NASDAQ:NAMS
$3.55B
Viking Therapeutics, Inc.
NASDAQ:VKTX
$3.34B
Who manages PTGX?
Protagonist Therapeutics, Inc. (PTGX) lists 11 active executives. The top listed executive is Carena Spivey, Executive VP & Chief Human Resources Officer.
Are PTGX insiders buying or selling?
Recent insider activity shows net selling of $41.47M.
Explore More
Continue the stock analysis
Jump to another research area for this company.